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Growing evidence implicates aberrant lipid signaling in Alzheimer’s disease (AD). While phospholipases A2 and C have been recently
shown to mediate key actions of amyloid -peptide (A) through a dysregulation of arachidonic acid and phosphatidylinositol-4,5-
bisphosphate metabolism, respectively, the role of phospholipase D (PLD) has so far remained elusive. PLD produces phosphatidic acid
(PA), a bioactive lipid involved in multiple aspects of cell physiology, including signaling and membrane trafficking processes. Here we
show that oligomericA enhances PLDactivity in culturedneurons and that this stimulatory effect does not occur upon ablation of PLD2
via gene targeting.A fails to suppress long-termpotentiation inPLD2-deficient hippocampal slices, suggesting thatPLD2 is required for
the synaptotoxic action of this peptide. In vivoPLD activity, as assessed by detection of phosphatidylethanol levels usingmass spectrom-
etry (MS) following ethanol injection, is also increased in the brain of a transgenic mouse model of AD (SwAPP). Furthermore, Pld2
ablation rescues memory deficits and confers synaptic protection in SwAPPmice despite a significant A load. MS-based lipid analysis
of Pld2mutant brains in the presence or absence of the SwAPP transgene unmasks striking crosstalks between different PA species. This
lipid analysis shows an exquisite acyl chain specificity and plasticity in the perturbation of PAmetabolism. Collectively, our results point
to specific molecular species of PA as key modulators of AD pathogenesis and identify PLD2 as a novel potential target for therapeutics.
Introduction
Cerebral accumulation of amyloid  (A) is believed to mediate
many aspects of Alzheimer’s disease (AD)-associated pathogen-
esis. A is produced by the sequential cleavage of the amyloid
precursor protein (APP) by - and -secretases. While A40 is
the predominant cleavage product, the longer peptide A42 is
more cytotoxic and aggregate-prone (Small and Gandy, 2006;
Haass and Selkoe, 2007; Vassar et al., 2009; De Strooper et al.,
2010). Although AD brains typically harbor senile plaques that
consist of insoluble aggregates of A, different assemblies of A,
including fibrils as well as soluble dimers, trimers and dodecam-
ers, may differentially contribute to AD pathogenesis at various
stages of this disorder (Lambert et al., 1998; Walsh et al., 2002;
Haass and Selkoe, 2007). Importantly, elevation of soluble A
oligomers strongly correlates with cognitive decline, consistent
with the synaptotoxic properties exhibited by these peptides in
various systems (Haass and Selkoe, 2007). For instance, A oli-
gomers disrupt synaptic plasticity, the trafficking of glutamate
receptors, dendritic spine dynamics and Ca2 homeostasis (De-
muro et al., 2005; Snyder et al., 2005;Hsieh et al., 2006;Haass and
Selkoe, 2007; Shankar et al., 2007; Green and LaFerla, 2008).
Importantly, recent work has suggested that A oligomers may
exert their effects upon binding to the cellular prion protein on
the neuronal membranes (Laure´n et al., 2009).
Mounting evidence indicates that A perturbs the metabo-
lism of intracellular signaling lipids and that this phenomenon
contributes to the pathogenic actions of this peptide (Hartmann
et al., 2007). In particular, work from our laboratory has shown
that A42 oligomers promote the hydrolysis of a major regula-
tory lipid phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]
through a stimulation of the phospholipaseC (PLC) pathway and
that preventing PI(4,5)P2 deficiency protects against the synapse-
impairing actions ofA (Berman et al., 2008). Similarly, A stim-
ulates cytosolic phospholipase A2 (cPLA2), thereby enhancing
the levels of arachidonic acid, and reduction of the relevant PLA2
isoform by genetic means confers protection against the peptide
(Sanchez-Mejia et al., 2008). Collectively, these studies suggest
that phospholipases may be primary mediators of A’s action.
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Phospholipase D (PLD), another family of phospholipases,
has also been implicated in AD pathogenesis (Singh et al., 1995;
Cai et al., 2006a; Brandenburg et al., 2008; Liu et al., 2009). PLD1
and PLD2, which are differentially localized in cells, hydrolyze
phosphatidylcholine (PC) into choline and a bioactive lipid,
phosphatidic acid (PA) (Freyberg et al., 2003; Jenkins and Fro-
hman, 2005; Roth, 2008; Donaldson, 2009). This lipid regulates
membrane dynamics and signaling processes through its intrinsic
physical properties (i.e., “cone shape”) and interaction with ef-
fector proteins (Jenkins and Frohman, 2005; Stace and Ktistakis,
2006; Haucke and Di Paolo, 2007; Roth, 2008; Raghu et al.,
2009a). In the present study, we tested the involvement of PLD2
in AD pathogenesis and more specifically, in the synaptotoxic
action of A oligomers. We reasoned that PLD2 was likely to
mediate the previously reported increase in total PLD activity
induced by A, based on the predominant localization of this
isozyme at the cell surface (Du et al., 2004), a major site of action
for A. We show that ablating PLD2 through genetic means
blocks the synaptotoxic action of A42 oligomers and rescues
memory deficits in a transgenic model of AD independently of
brain A levels.
Materials andMethods
Cell culture.PC12 cells weremaintained inDMEMwith sodiumpyruvate
(Invitrogen) supplemented with 5% fetal bovine serum, 10% horse se-
rum, glutamine (4 mM), penicillin (200 U/ml), streptomycin (200 g/
ml); cells weremaintained at 37°C in 5%CO2. Twenty-four hours before
transfection, PC12 cells were plated (at 50% confluence) on coverslips
precoated with polylysine (20 g/ml) for 1 h at 37°C. Transfections of
GFP-mouse PLD2 construct (kind gift from Michael Frohman, SUNY,
Stony Brook,NY), whichwas previously described (Du et al., 2004), were
obtained using Lipofectamine 2000 (Invitrogen). Primary cultures from
cortical neurons were generated from newborn wild-type mice. Briefly,
cortices were dissected out, trypsinized for 30 min, and then cortical
cells dissociated with a Pasteur pipette and plated on poly-ornithine-
coated 10 mm dishes at a density of 25,000 cells/cm2 in Neurobasal-A
medium containing 1mM kynurenic acid to reduce enhanced synaptic
transmission due to the high density of the cultures. Treatments with
oA42 were typically performed after 15 days in vitro, with 200 nM
concentration and with time duration of 4 h for primary neuronal
cultures and 5, 30 and 60 min in PC12 cells. Ionomycin was used with
2 M concentration for 30 min.
Peptide preparation. A oligomers were prepared as described previ-
ously (Dahlgren et al., 2002). Synthetic A (1-42) was purchased from
American Peptide and stored at20°C. The vial containing the peptide
was allowed to equilibrate to room temperature for at least 30min before
resuspension. In a fume hood the peptide was diluted to 1 mM in
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) by pipette mixing and imme-
diately aliquoted in polypropylene microcentrifuge tubes. The solution
was vortexed briefly and allowed to evaporate in the fume hood for 2 h.
The resulting peptide films were dried in a Speed Vac for 10min at 800
g and stored at20°C. Before use, the peptide film was resuspended to 1
mM in DMSO by pipette mixing followed by bath sonication for 10 min.
The solution was aliquoted in polypropylene microcentrifuge tubes and
stored at 20°C. The peptide was used within 2 weeks of dilution in
DMSO. Oligomeric forming conditions: the 1 mM DMSO solution was
diluted to 100M in cold PBS, vortexed for 30 s, and incubated overnight
at 4°C (minimum incubation of 12 h). Immediately before use, the A-
PBS solution was further diluted in culture media to the required final
concentration and vortexed briefly. This preparation contains a mixture
of monomers, trimers and tetramers as well as traces of dimers and high
molecular weight oligomers, as shown previously (Berman et al., 2008).
Mouse strains and breeding strategy. The genetic background of the
Pld2 mice is mixed (C57BL/6–129svj). Pld2/ females were crossed
withTg2576males (Taconic;mixed backgroundC57BL/6-SJL/N),which
express human APP carrying the double mutation K670N and M671L
found in a Swedish family with early onset of Alzheimer’s disease, under
the regulation of the hamster prion protein promoter (Hsiao et al., 1996).
From the F1 hybrid generation we used as breeders Pld2
//no tg fe-
males and Pld2//SwAPP males. For all our animal studies we used
littermate mice (or in some cases, mice sharing at least one parent) de-
rived from the F2 generation. The survival rate of adult mice was90%
for all genotypes within the first 12months of age (and thus the impact of
Pld2 deletion on the survival of SwAPP mice was not investigated
further).
ELISA analysis. Brains were homogenized in 10 volumes of 50 mM
Tris-HCl buffer, pH 7.6, containing 250 mM sucrose and protease inhib-
itor cocktail (Sigma). Soluble and total Awere extracted in 0.4% dieth-
ylamine (DEA) and 70% formic acid, respectively, as previously
described (Schmidt et al., 2005). Levels of full-length A 1-40 and 1-42
were quantified using antibodies donated by Centocor according to pre-
viously published ELISA procedures (Schmidt et al., 2005). Murine A
was measured according to a previously published procedure (Burns et
al., 2003).
Western blot analysis. The DEA fraction of brain extracts from Pld2/
SwAPPmutant mice was immunoblotted using a rabbit polyclonal anti-
body to the COOH terminus of PLD (kind gift from Dr. Sung Ho Ryu,
Pohang University of Science and Technology, Pohang, South Korea),
rabbit polyclonal antibody to PLD1 (Cell Signaling Technology), mouse
monoclonal antibody to APP (6E10, Covance), mouse monoclonal an-
tibody to PSD95 (6G6–1C9, Abcam), rabbit polyclonal synaptophysin
(G95, kind gift from Dr. Pietro De Camilli, Yale University, New Haven,
CT), and a mouse monoclonal antibody to -tubulin (B-5-1-2, Sigma).
Quantification was performed using ImageJ software.
PLDactivity in neuronal cultures.Ten-day-old neuronswere incubated
with [ 3H]palmitic acid (2Ci/ml) for5 d to label cellular phospholip-
ids. Following treatments with vehicle or oA42, neurons were incu-
bated in the presence of 0.3% butanol for 30 min, which leads to the
production and accumulation of [ 3H]phosphatidylbutanol via a PLD-
specific transphosphatidylation reaction. Radiolabeled lipids, including
phosphatidylbutanol, were isolated by solvent extraction and separated
by thin-layer chromatography. The total amount of [ 3H]phosphatidyl-
butanol is expressed as a percentage of total 3H-labeled lipids (Morris et
al., 1997).
Confocal microscopy: analysis of GFP-PLD2 internalization. Twenty-
four hours after transfection with a plasmid encoding GFP-PLD2, PC12
cells were incubated with vehicle or 200 nM oA42 for 5, 30 and 60 min.
Other treatments included 2 M ionomycin (Sigma-Aldrich), 2 mM
EGTA (Sigma-Aldrich), 250 nM U-73122 (Calbiochem), and 20 M AA-
COCF3 (Calbiochem) for 30 min, as indicated in the figure legend. Cells
were then washed in phosphate buffer and fixed with 4% paraformalde-
hyde. Confocal z-stack images (0.5 m) of PC12 were obtained using a
Nikon EZ-C1.2.30 confocal microscope and an oil-immersion objective
(100). Quantification of GFP intensity was calculated using the ImageJ
software: for each cell in a given image, a line intensity profile across the
cell was obtained. The relative decrease in plasmamembrane localization
was calculated as the ratio between the plasma membrane fluorescence
intensity and the average cytosolic fluorescence intensity, as previously
described (Berman et al., 2008).
Electrophysiology. Transverse hippocampal slices (400 m) were cut
with a tissue chopper (EMS, PA) andmaintained in an interface chamber
at 29°C for 90 min before recording, as previously reported (Puzzo et al.,
2005). CA1 field EPSPs (fEPSPs) were recorded by placing both the stim-
ulating and the recording electrodes in CA1 stratum radiatum. Basal
synaptic transmission (BST) was evaluated either by plotting the stimu-
lus voltages (V) against slopes of fEPSP, or by plotting the peak amplitude
of the fiber volley against the slope of the fEPSP, to generate input-output
relations. During baseline recordings, responses were evoked at an inten-
sity of35% of themaximum evoked response LTPwas induced using a
-burst stimulation (4 pulses at 100 Hz, with bursts repeated at 5 Hz and
each tetanus including three 10-burst trains separated by 15 s). oA42
was applied for 20 min before the -burst.
Fear conditioning. The capacity of the mice for contextual and cued
memory was tested as before (Paylor et al., 1994; LeDoux, 2000; Gong et
al., 2006), with slightmodifications. Briefly, mice were first exposed for 2
min to the context before the onset of a tone (a 30 s, 85 dB sound at 2800
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Hz) serving as a conditioning stimulus (CS). In the last 2 s of the CS,mice
received a 2 s, 0.50 mA foot shock [unconditioned stimulus (US)]
through the bars of the floor. Freezing, which is defined as a species-
specific defensive reaction characterized by lack ofmovement, associated
with crouching posturewasmeasured right after the end of theCS/US for
30 s using the Freezeview software (MEDAssociates Inc.). The contextual
memory test was performed 24 h later, by reexposure of the mice to the
same context and by measuring the proportion of freezing time during 5
min. To evaluate cued fear learning, 24 h after contextual testing, mice
were placed into a novel context for 2 min (pre-CS test), followed by an
exposure to theCS for 3min (CS test), duringwhich freezingwasmeasured.
No differences were found between the six genotypes in this control test
(data not shown). For all the fear conditioning experiments, the condition-
ing chamber is located inside a sound-attenuating box (72 cm 51 cm 48
cm).AclearPlexiglaswindow(2cm12cm20cm)allows the researcher
to digitally record themouse performance with a camera placed on a tripod
and connected to Freezeframe software (MEDAssociates Inc.).
Radial armwater maze.The test was performed as before (Trinchese et
al., 2008) in a white tank filled withmilky water, and containing stainless
steel walls positioned to produce six arms, radiating from a central area.
Spatial cues were presented on the walls of the testing room. At the end of
one of the arms there was a clear 10 cm Plexiglas submerged (1.5 cm)
platform, which remained in the same location for every trial in 1 d, but
was moved randomly each day. On each trial, the mouse started the task
from a different randomly chosen arm. The mouse could not use long-
termmemory of the location of the platformon previous days, but had to
rely on the short-term memory of its location in the same day based on
spatial cues. Each trial lasted 1 min and errors are counted each time the
mouse entered the wrong arm with four paws, or needed20 s to reach
the platform. After each error, the mouse was gently pulled back to the
start arm for that trial. After four consecutive trials, it was placed in its
home cage for 30 min, and then administered a retention trial. Testing
was considered complete when wild-type mice reached asymptomatic
performance (below one error on trials 4 and 5; 10 training days). Scores
for each mouse on the last 3 d of testing were averaged and used for
statistical analysis. All behavioral experiments were done blind to the
genotype. Visible-platform tests to detect visual, motor or motivational
impairments were performed in the same pool, but without arms and
with the platform marked with a black flag, once the radial arm water
maze (RAWM) study was completed. Platform location was varied ran-
domly to eliminate any contribution of external spatial cues. Four trials
per day were given over 2 d. Each animal was allowed to swim for 1 min
from a random location. Once the mouse reached the platform (or with
help if it did not reach it on its own), it was allowed to rest there for 30 s.
Failures to reach the platform are scored as 60 s. Data were recorded
using a ceiling-mounted camera and analyzed with an HVS-2020 video
tracking system.
In vivoPLDactivity.Nontransgenic and SwAPPmicewere injected intra-
peritoneally with 3 g/kg ethanol. Mice were killed 1 h postinjection. Fore-
brains were then removed from the mice and levels of phosphatidylethanol
(PEtOH)producedvia aPLD-specific transphosphatidylation reactionwere
measured in lipid extracts via mass spectrometry, as described below.
Mass spectrometry. Lipid extracts were prepared from mice forebrain
using a modified Bligh and Dyer method and analyzed by liquid
chromatography-mass spectrometry (LC-MS). Polar glycerophospho-
lipids and sphingolipids were separated via a Luna silica column (3 m,
2 mm  150 mm; Phenomenex) with a solvent gradient of 100% chlo-
roform/methanol/water/ammonia solution (90:9.5:0.5:0.32, v/v) chang-
ing to 100% chloroform/methanol/water/ammonia solution (50:48:2:
0.32, v/v) over 40 min (Pettitt et al., 2001). Lipid species were measured
using a triple quadrupole instrument ABI 4000 Q-Trap (Applied Biosys-
tems) operated in a multiple-reaction monitoring (MRM) mode. Both
PA and PEtOH species were measured using MRM transition pair of
parent ion m/z to fatty acyl chain m/z using instrument settings as de-
scribed previously (Chan et al., 2008; Fei et al., 2008). PA levels were
quantified by referencing to known amounts of spiked internal standard
diC17-PA (Avanti Polar Lipids). PEtOH levels were referenced to spiked
internal standard diC16-PEtOH (Avanti Polar Lipids), which was added
in excess of endogenous levels of this species.
Statistics. Statistical analysis was performed using two-tailed equal
variance and Student’s t test, unless indicated otherwise. All the experi-
ments were performed in blind to the genotypes.
Results
Reduction in PLD2 levels blocks A-induced PLD activation
To begin to address the role of PLD in A pathogenesis and to
determine which of the two isoforms may be stimulated by A,
we tested whether oligomeric A signaling alters the subcellular
localization of either PLD1 or PLD2. Indeed, previous work from
others has indicated that stimulation of these enzymes enhances
their transport to and from the cell surface (Du et al., 2003; Laul-
agnier et al., 2004). Pheochromocytoma cell line PC12 was trans-
fected with constructs encoding either GFP-PLD1 or GFP-PLD2,
whose localizationwas analyzed after an acute treatmentwith 200
nMA42 oligomers (oA42). As expected (Du et al., 2004), in the
absence of treatment or in the presence of vehicle, the fluores-
cence of GFP-PLD2 was concentrated at the plasma membrane
(Fig. 1A,B) while the fluorescence of GFP-PLD1 was more intra-
cellular (data not shown), likely reflecting the predominant lo-
calization of this isoform in the Golgi complex as well as in
secretory granules and endosomes (Jenkins and Frohman, 2005;
Roth, 2008; Bader and Vitale, 2009). Incubation of PC12 cells
with 200 nM oA42 for 5, 30, and 60 min did not produce an
obvious effect in localization pattern of GFP-PLD1 (data not
shown). On the other hand, while incubation of PC12 cells with
oA42 did not significantly affect the localization of GFP-PLD2
after 5min, it triggered a partial internalization of this probe after
30 and 60 min (Fig. 1A,B). This effect was mimicked by a treat-
ment with 2 M ionomycin, a Ca2 ionophore and a known
PLD2 activator (Kim et al., 1999), and it was blocked by preincu-
bation with 2 mM EGTA, an extracellular Ca2 chelator, indicat-
ing that the oA42 effect on PLD2 is Ca2-dependent (Fig. 1C).
Based on previous work showing an activation of both the PLC
and cPLA2 pathways downstream of A (Kanfer et al., 1998;
Kriem et al., 2005; Berman et al., 2008; Sanchez-Mejia et al., 2008;
Oliveira and Di Paolo, 2010), we tested whether A-induced
GFP-PLD2 relocalization was dependent upon PLC or cPLA2
using pharmacological inhibitors (i.e., U-73122 and AACOCF3,
respectively). While the PLC inhibitor had no effect on the local-
ization of GFP-PLD2, the cPLA2 inhibitor blocked the relocaliza-
tion of GFP-PLD2 in response to oA42, suggesting that this
phenomenon is independent or upstream of PLC but likely
downstream of cPLA2 (Fig. 1D).
To test whether PLD2 mediates cytotoxic actions of A
oligomers, we developed a mouse genetic model lacking PLD2
(supplemental Fig. 1A,B, available at www.jneurosci.org as
supplemental material). Mutant mice do not exhibit any overt
phenotype. Western blot analysis using specific antibodies
showed that the PLD2 immunoreactivity is absent and approxi-
mately decreased by 50% in adult brain tissue derived from
Pld2/ and Pld2/ mice, respectively (see Fig. 6A). To con-
firm that PLD2 ablation produces a significant decrease in total
PLD activity in brain tissue, we developed an in vivo PLD activity
assay relying on the intraperitoneal injection of adult mice with
ethanol andmeasurement of phosphatidylethanol (PEtOH) (i.e.,
the product of PLD) 1 h postinjection in the adult brain of
Pld2/ and Pld2/ mice using liquid chromatography-mass
spectrometry (LC-MS) (Pettitt et al., 2001; Chan et al., 2008).We
found a 40% decrease of PEtOH levels in the brain of Pld2/
mice (supplemental Fig. 1C, available at www.jneurosci.org as
supplemental material), thus indicating that PLD2 contributes a
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significant fraction of total PLD activity in
the adult brain (with the remainder likely
accounted for by PLD1).
To begin to determine the role of PLD2
in the A signaling pathway, we tested
whether the oligomeric peptide prepara-
tion used in this study (oA42) enhances
total PLD activity in primary cortical neu-
rons. Indeed, previous work from others
had shown that treatment of neuronal cell
lines with micromolar concentrations of
A25-35 increases PLD activity (Singh
et al., 1995, 1998; Kanfer et al., 1998;
Oliveira and Di Paolo, 2010). Here, total
PLD activity was analyzed in cultured
neurons following metabolic labeling
with [3H]myristic acid in the presence of
low concentrations of 1-butanol and
quantification of PLD’s transphosphati-
dylation product, phosphatidylbutanol
(Fig. 2). In the absence of A oligomer
treatment, basal PLD activity was signifi-
cantly decreased by 30  11% and 74 
13% in Pld2/ and Pld2/ neurons, re-
spectively. Remarkably, oA42 applica-
tion led to a2-fold increase in total PLD
activity in Pld2/ neurons (Fig. 2), an
effect comparable to that obtained with 2
M ionomycin (i.e., a 92 11% increase,
n 6, p 0.001). However, oA42 failed
to increase this activity in Pld2/ as well
as in Pld2/ neurons (Fig. 2), indicating
that the PLD2 isoform is involved in the
A signaling cascade.
Ablation of PLD2 blocks the
suppressive effect of A oligomers
on LTP
If the activation of PLD is necessary for oA42-induced synaptic
dysfunction, the ablation of Pld2may confer a resistance against
the peptide with respect to neurophysiology. To test this, the
effect of oA42 on synaptic transmission was assessed in adult
hippocampal slices from Pld2/ and Pld2/ mice, where re-
cordings were performed in the CA1 hippocampal region after
stimulation of the Schaffer collateral pathway. First, basal neuro-
transmission (input-output) was investigated and found to be
normal in Pld2/ slices in the absence of the peptide (supple-
mental Fig. 2, available at www.jneurosci.org as supplemental
material). Next, long-term potentiation (LTP) was induced by a
tetanic stimulation after exposing slices from the two genotypes
to 200 nM oA42 or vehicle for 20min. LTP in Pld2/ slices was
comparable to that obtained in Pld2/ slices in the presence of
vehicle (Fig. 3). However, while oA42 partially impaired LTP in
Pld2/ control slices, as reported before (Lambert et al., 1998;
Vitolo et al., 2002;Haass and Selkoe, 2007), the effect of this crude
oligomer preparation onLTPwas strongly suppressed inPld2/
slices (Fig. 3), suggesting that the ablation of PLD2prevents A42
oligomers from exerting their synaptotoxicity.
PLD activity is increased in the brain of a transgenic model
of AD
To understand the in vivo relevance of the PLD pathway in an AD
model, we subjected the transgenic line Tg2576, which expresses
the Swedish APP (SwAPP) mutant (Hsiao et al., 1996) to acute
ethanol injections, so as to conduct in vivomeasurements of PLD
activity as described above. We used aged (i.e., 14-month-old)
mice for these studies, because A levels are known to increase in an
age-dependent fashion in the forebrain of these animals, thus lead-
ing to well established cognitive deficits (Hsiao et al., 1996). We
found that total PEtOHlevels are increasedby2511%(n6,p
0.05) in the forebrain of SwAPPmice relative to controls, indicating
an overall enhancement of PLD activity in mutant animals. More
specifically, there was a significant increase in a subset of molecular
species of PEtOH (32:1, 34:2, 34:1 and 34:1) and an overall trend for
an increase in the other PEtOH species analyzed, with the exception
of 38:2 (Fig. 4; see also supplemental Table 1, available at www.
jneurosci.org as supplementalmaterial for absolute levels of PEtOH
species).This is toourknowledge the first in vivo evidence in support
of a dysfunction of the PLD pathway in an ADmouse model.
Reducing PLD2 levels ameliorates the memory deficits of a
transgenic model of AD
Next, the impact of Pld2 ablation on learning behavior was as-
sessed in the SwAPP mice. To this goal, mice of the three Pld2
genotypes (/,/,/) in the transgenic (SwAPP) or non-
transgenic (no SwAPP) background were subjected to the con-
textual fear conditioning paradigm, which assesses a form of
emotional learning that requires normal amygdala and hip-
Figure 1. PLD2 lies in the A signaling pathway. A, PC12 cells were transfected with a plasmid expressing GFP-PLD2. Repre-
sentative examples show internalization of GFP-PLD2 after treatments with 200 nM oA42. Pictures show the fluorescence of
GFP-PLD2. B, oA42 (200 nM) was applied to PC12 cells in cultures for 5, 30, and 60 min, and relocalization of GFP-PLD2 was
quantified as the PM/cytosol ratio (0min, n 31; 5min, n 29; 30min, n 32; 60min, n 30). C, Effect of 30min treatments
with ionomycin (2M) and EGTA (2mM) on the localization of GFP-PLD2 in the presence or absence 200 nM oA42. The number of
cells analyzedwas as follows: vehicle (n 37), oA42 (n 33), ionomycin (n 26), EGTA (n 33), EGTA oA42 (n 38).
D, Effect of 30 min treatments with pharmacological inhibitors of PLC (U73122, 250 nM) and PLA2 (AACOCF3, 20 M) on the
localization of GFP-PLD2 in the presence or absence of 200 nM oA42. The number of cells analyzed was as follows: vehicle (n
97), oA42 (n 81), U73122 (n 41), U73122 oA42 (n 42), AACOCF3 (n 50), AACOCF3 oA42 (n 45). ForB–D,
values denote means SEM. *p 0.05, ***p 0.001).
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pocampus function. In this task, an innocuous conditioned stim-
ulus (tone) elicits fear response after being associatively paired
with an aversive unconditioned stimulus (footshock). The fear
response is measured by the frequency of freezing behavior,
which is defined as a stereotyped motionless crouching posture.
For these experiments, 5- to 6-month-old mice were used, because
our preliminary studies had shown that SwAPP mice, in this age
category, exhibit learning deficits, which are not associated with a
significantneuriticplaqueburdenand thus likely reflect the effectsof
solubleA assemblies.Mice fromall six genotypes did not showany
major differences in the baseline levels (pretesting). As expected, the
SwAPPmice, unlike nontransgenic mice, exhibited little contextual
fear response 24 h after the pretest, thus denoting an impairment in
contextual learning in the presence of a normal copy number for
Pld2. However, transgenic mice lacking one (SwAPP/Pld2/) or
two (SwAPP/Pld2/) copies of Pld2 performed better than the
SwAPP/Pld2/mice (Fig. 5A), suggesting that genetic ablation of
Pld2 is protective.
Next, mice were subjected to a second learning task, the
RAWM paradigm, which assesses spatial working memory. In
this test, mice have to find a hidden platform, at the end of one of
six arms, remaining in the same location for every trial in 1 d, but
moved to another location from day to day. For each trial, mice
start the task from a different randomly chosen arm. After four
consecutive trials mice are returned to the cage and submitted to
a fifth trial (retention test) 30 min later. While the SwAPP/
Pld2/mice showed impairedmemory after 10 d of training (cf.
Trinchese et al., 2008), mice lacking one (SwAPP/Pld2/) or
two (SwAPP/Pld2/) copies of Pld2 perform similarly as ani-
mals that do not express SwAPP (Fig. 5B), indicating that, as in
the fear conditioning test, reduction of PLD2 was protective for
the deficits induced by overexpression of the transgene and in-
creased A load. The six groups of mice analyzed showed no
overall major differences in the escape latency in the visible plat-
form task, as well as in the swimming speed (supplemental Fig. 3,
available at www.jneurosci.org as supplemental material) indi-
cating that differential vision, locomotor activity or motivation
did not influence the outcome of the RAWM testing.
Reducing PLD2 levels maintains synaptic protein levels in a
transgenic model of AD
Since a reduction or ablation of PLD2 confers protection against
the deleterious effects of oA42 on LTP (Fig. 3) and of SwAPP
overexpression on learning and memory (Fig. 5), a likely possi-
bility is that lack of PLD2 exerts a synapse-protecting effect. To
test this, levels of presynaptic and postsynaptic proteinswhich are
known to be affected by A elevation and SwAPP overexpression
(Almeida et al., 2005) were investigated. We found that ablation
of either one or two copies of PLD2 does not affect the forebrain
levels of synaptophysin (presynaptic marker) and PSD95
(postsynaptic marker) in the absence of SwAPP transgene. How-
ever, while expression of the SwAPP transgene leads to a signifi-
cant decrease in the levels of PSD95 and, to a lesser extent,
synaptophysin, PLD2 ablation restored the levels of these two
synaptic proteins to normal levels, with partial phenotypes ob-
served for SwAPP/Pld2/mice (Fig. 6). These biochemical data
are in agreement with the notion that PLD2 ablation may confer
Figure 2. Ablation of PLD2 reduces basal PLD activity and abolishes the stimulatory effect of
A oligomers on PLD activity in cultured neurons. Primary cortical cultures were labeled with
[ 3H]myristic acid at day 12, treatments were performed at day 15, lipids were subsequently
extracted and the ratio [ 3H]phosphatidylbutanol counts/total counts was used as ameasure of
PLD activity. Four-hour treatments with vehicle or oA42 200 nM were performed before PLD
activity measurement in Pld2/ (n 19 and 12 for vehicle and oA42 treatment, respec-
tively), Pld2/ (n 7), and Pld2/ (n 5 and 7, respectively). Values denotemeans
SEM. ns, Nonsignificant. *p 0.05, **p 0.01, ***p 0.001.
Figure 3. LTP is unaffected by oA42 in Pld2/ hippocampal slices. There was no differ-
ence in LTP between Pld2/ slices and Pld2/ slices in the presence of vehicle (F(1,17)
0.01, p  0.9473). Although Pld2/ slices showed a reduction of LTP following bath
application of 200 nM oA42 (F(1,16) 5.19, p 0.0367, relative to vehicle), LTP was not
reduced by the peptide in Pld2/ slices (F(1,14) 0.01, p 0.9185, relative to vehicle).
fEPSP, CA1 field-EPSP. The bar represents the time of bath application of oA42. The three
arrows represent the -burst stimulation used to induce potentiation. Animals were 3
months old. Values denotemeans SEM (n 8–9). Note that the vehicle traces for both Pld2
genotypes (i.e., black filled triangles and circles) are largely overlapping.
Figure 4. PLD activity is enhanced in the forebrain of aged SwAPP mice. Mice, with and
without SwAPP transgene, were injected with 3 g/kg ethanol, and their forebrain lipids were
extracted and subjected to LC-MSanalysis. Theproduction andaccumulationof PEtOHwasused
asa reporterof in vivoPLDactivity. Relative individualPEtOHspeciesweremeasuredinmutantmice
comparedwithcontrolmice.Thenomenclaturefor fattyacidcompositionofphospholipids isdenoted
as total chain length/number of unsaturated bonds. Values denote mean SEM (n 6). **p
0.01, ***p 0.001. Absolute amounts of the various molecular species of PEtOH are presented in
supplemental Table 1, available atwww.jneurosci.org as supplementalmaterial.
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synaptic protection in the context of the
SwAPP background. Because synaptic
protein levels are not altered by the Pld2
genotype (Fig. 6) and that the electro-
physiology analysis shows a normal
input-output relationship in mutant hip-
pocampi in the absence of SwAPP trans-
gene (supplemental Fig. 2, available at
www.jneurosci.org as supplemental ma-
terial), we speculate that the protective
mechanism likely does not involve a gross
increase in the number of functional syn-
apses in the mutant.
Effect of the APP transgene expression
and PLD2 ablation on brain
PA metabolism
To gain insight into the molecular basis
underlying AD pathogenesis as well as the
protection conferred by PLD2 ablation,
we focused our analysis on PA, the product of PLD. Amass spec-
trometry analysis ofmutant animals was performed covering dif-
ferent species of PA. Total forebrain lipids were extracted from
11- to 12 month-old Pld2/ and Pld2/mice in the presence
or absence of the SwAPP transgene and analyzed using LC-MS.
Three classes of potential lipid alterations were investigated: (1)
changes produced by the ablation of PLD2; (2) changes occurring
in response to the overexpression of SwAPP; and (3) changes
reflecting interactions between the SwAPP transgene and the
Pld2 genotypes. Results are expressed either in the form of molar
percentages in a table (supplemental Table 2, available at www.
jneurosci.org as supplemental material) or in the form of bar
graph relative to control brains (Pld2/, no SwAPP) (Fig. 7).
The data show that ablation of PLD2 significantly decreases
the levels of two molecular species of PA based on the different
fatty acyl composition (see legend), namely, PA 32:1 (50%) and
38:4 (40%), while a trend for a decrease (20%) was observed
for two other species, PA 34:1 and 34:0 (Fig. 4B; supplemental
Table 2, available at www.jneurosci.org as supplemental mate-
rial). Surprisingly, thePA32:0and38:2 specieswereupregulated (by
25% and 30%, respectively), suggesting the occurrence of com-
pensatory mechanisms in Pld2 knock-out brains. Indeed, the total
amount of PA (i.e., sum of all species measured) was overall unaf-
fectedby thePld2genotype, thusdenotinga tremendousplasticity in
the metabolism of PA. In agreement with this report’s findings
showing increased PLD activity in response to A application in
neuronal cultures (Fig. 2), SwAPPoverexpression leads to a selective
35% increase in a low abundance, yet, functionally critical (Raghu et
al., 2009b) (see Discussion) species of PA, PA 34:2, of the 11molec-
ular species of PA analyzed. Although PA 34:2 is not affected by the
Pld2 genotype in the absence of the transgene, it no longer accumu-
lates in the SwAPP forebrain upon ablation of PLD2, suggesting it
may be a bona fide product of PLD2 upon SwAPP overexpression.
Reduction in PLD2 levels does not alter APP or A levels in
SwAPP mice
An important question is whether the rescue of the learning per-
formance reflects a reduction in amyloidogenesis. Thus a bio-
chemical analysis of the brains from 12-month-old SwAPP/Pld2
mice was conducted after the RAWM test. Western blot analysis
showed that full-length APP levels are not affected by ablation of
one or two copies of Pld2 (Fig. 8A,B). Importantly, no significant
differences were found in the levels of soluble and insoluble hu-
man A1-40 and A1-42 (Fig. 8C,D) and total murine A1-40 and
A1-42 (supplemental Fig. 4, available at www.jneurosci.org as
supplemental material) upon disruption of Pld2 gene, as mea-
sured by ELISA. Overall, ablation of PLD2 protected from the
memory deficits in the SwAPP mice, and this protection was
Figure 5. PLD2 ablation improves learning and memory in SwAPP mice. A, SwAPP mice (Tg2576) were crossed with Pld2
knock-out mice and the resulting offspring [Pld2//no tg (n 14); Pld2//no tg (n 14); Pld2//no tg (n 11);
Pld2//SwAPP (n10);Pld2//SwAPP (n12);Pld2//SwAPP (n11)]were subjected to training for contextual fear
memory, whichwas assessed 24 h after the foot shock, using 5- to 6-month-old animals. *p 0.05 in Student’s one-tail t test.B,
Twelve-month-oldmicewere subjected to RAWM testing. Errors were scored in the last 3 d of testing. The n valuewas 8 for all the
genotypes, except for Pld2//SwAPP (n 7) and Pld2//SwAPP (n 6). **p 0.01. Values denote means SEM.
Figure 6. PLD2 ablation confers synaptic protection in the forebrain of SwAPP mice. After
RAWM testing, forebrains from 12-month-old Pld2/SwAPP mice were processed for biochem-
ical analysis. A, Protein levels were evaluated by Western blot analysis of PLD2, PLD1, PSD95,
synaptophysin, and tubulin (representative blots are shown). B, Quantification of PSD95 levels
by densitometric analysis. C, Quantification of synaptophysin levels by densitometric analysis.
Values denote means SEM. n 4, *p 0.05.
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concomitantwith a highA burden further suggesting that PLD2
acts downstream of A signaling in this AD model.
Discussion
Previous studies have implicated PLD in AD pathogenesis either
as a mediator of APP trafficking, presenilin regulation or down-
stream target of A (Kanfer et al., 1986, 1996, 1998; Singh et al.,
1997a,b, 1998; Cai et al., 2006a,b; Jin et al., 2007; Brandenburg et
al., 2008; Liu et al., 2009; Oliveira and Di Paolo, 2010). Impor-
tantly, an increase in total PLD activity was reported in AD brain
homogenates, using an in vitro enzymatic assay (Kanfer et al.,
1996). However, these studies have established neither the patho-
physiological relevance of the PLD pathway in AD in vivomodels
nor the precise role of PLD2 in AD patho-
genesis. For instance, cell culture studies
have established a role for PLD1, but not
PLD2, in the trafficking of both APP and
PS1 with important implications for APP
metabolism and A secretion (Cai et al.,
2006a,b; Liu et al., 2009; Oliveira and Di
Paolo, 2010). Our study suggests that
PLD2, unlike PLD1, may be a down-
stream target of A oligomers.
Although the synaptotoxic actions of
A oligomers are beginning to be under-
stood, the underlying molecular mecha-
nisms are still unclear. This study provides
experimental and genetic evidence dem-
onstrating that PLD, and PLD2 in partic-
ular, is pathophysiologically relevant in
the context ofmousemodels of AD and in
the synaptotoxic actions of A42 oli-
gomers. Specifically, PLD2 ablation con-
fers protection against the synapse-
impairing actions of A42 in an ex vivo model of synaptic
plasticity (Fig. 3) and against the cognitive deficits and synapse
impairment induced by overexpression of SwAPP (Figs. 5, 6).
This protective effect occurs despite high A levels (Fig. 8), as
observed previously in various other AD mouse models (Rober-
son et al., 2007; Sanchez-Mejia et al., 2008; Dziewczapolski et al.,
2009; Gimbel et al., 2010). Thus, our data are consistent with
scenarios whereby PLD2 and its enzymatic product (1) mediate
key signaling cascades downstream of A; (2) regulate the (cell
surface) availability of putative A receptors at synapses; or (3)
alter the capacity of A to bind to its putative receptors. Because
a pool of PLD isozymes is associated with lipid rafts and that A
has a high affinity for these lipid microdomains (Yanagisawa,
2007; Ariga et al., 2008; Hebbar et al., 2008), a tantalizing hypoth-
esis is that PLD2 ablation may disrupt the raft-dependent signal-
ing of A. Importantly, ablation of one or two copies of PLD2not
only reduces basal PLD activity, but it also blocks oA42-induced
increase in this activity. Therefore, the protective effect may re-
flect either changes in PLD activity or a combination of both.
Finally, although our data suggest that neurons expressing re-
duced amounts of PLD2may play a central role in this protective
effect, a contribution of other cell types, such as glial cells, cannot
be ruled out.
Importantly, our results expand on previous studies show-
ing that impairment of signaling lipids plays a key role in AD
pathogenesis in animal models. Specifically, A oligomers
have been shown to dysregulate the PLC and PLA2 pathways
with major implications for the signaling downstream of
PI(4,5)P2 and arachidonic acid in the brain (Singh et al., 1995;
Berman et al., 2008; Sanchez-Mejia et al., 2008). This study pro-
vides further support to the hypothesis that phospholipase
signaling may be globally altered in AD and that A-induced
Ca2-dyshomeostasis through glutamate receptors or other
mechanisms may be underlying these changes. Indeed, we find
that oligomeric A affects the localization of PLD2 in a manner
dependent upon extracellular Ca2, thus suggesting a role for
Ca2 entry in the activation of three phospholipase families,
PLC, PLA2 and PLD2. Here, we show that pharmacological
inhibition of PLC does not prevent A-induced PLD2 relocal-
ization, suggesting that PLD2 either lies upstream or acts in-
dependently of PLC in the A signaling pathway (Fig. 1D).
Moreover, we show that PLD2 relocalization induced by
Figure 7. Effect of SwAPP overexpression and Pld2 genotypes on PA levels. After RAWM testing, forebrains from12-month-old
Pld2/SwAPPmicewere processed for lipid biochemical analysis. Forebrain lipidswere extracted fromPld2/ andPld2/mice
with and without SwAPP transgene and subjected to LC-MS analysis. Relative amounts of PA species were measured in mutant
mice compared with control mice (Pld2/, no SwAPP). Values denote mean SEM (n 6–8). *p 0.05, **p 0.01,
***p 0.001. The nomenclature for fatty acid composition of phospholipids is denoted as total chain length/number of unsat-
urated bonds. Absolute amounts of the various molecular species of PA are presented in supplemental Table 2, available at
www.jneurosci.org as supplemental material.
Figure8. Effect of SwAPPoverexpression andPld2genotypes onAPPprocessing.A–D, After
RAWM testing, forebrains from 12-month-old Pld2/SwAPP mice were processed for biochem-
ical analysis. A, Protein levels were evaluated by Western blot analysis of APP and tubulin
(representativeblots are shown).B, Quantificationof full-lengthhumanAPP levelswasdoneby
densitometric analysis. Values denote means SEM (n 6). C, D, ELISA analysis of the levels
of soluble A40 and A42 (C), and insoluble A40 and A42 (D). Values denote means
SEM; Pld2//SwAPP (n 6); Pld2//SwAPP (n 8); Pld2//SwAPP (n 7).
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oA42 is blocked by inhibition of cPLA2 (Fig. 1D), in agree-
ment with other studies showing that PLD2 activation occurs
downstream of Ca2 entry and cPLA2 stimulation in a lym-
phocytic leukemia cell line (Kim et al., 1999). More careful
molecular genetic/genetic approaches should provide a defin-
itive answer concerning the crosstalk between these enzymes
and their precise role in this cytotoxic signaling pathway.
To understand the impact on PLD activity and PA metabo-
lism of Pld2 ablation, SwAPP overexpression as well as the inter-
action between these two genetic manipulations, we have used
LC-MS. The in vivo PLD activity assay relies on themeasurement
of PEtOH,which is the product of PLDcatalysis in the presence of
ethanol. In contrast to PA, PEtOH is a specific product of PLD
and is very stable, due to its poor consumption by lipases
(Gustavsson, 1995). Importantly, changes in specific molecular
species of PEtOH can be correlated with those in the correspond-
ing species of PA, thus providing clues on the contribution of
PLD to the synthesis of specific pools of PA. Results from our
analysis suggest that a dysregulation of PLD function and PA
metabolism may be associated with AD pathogenesis and that
specific pools of PA may be affected. Indeed, while brains from
SwAPPmice showed an overall increase in PEtOH levels and thus
total PLD activity (Fig. 4A), a more detailed analysis of PEtOH
species showed that only a subset of species, such as PEtOH 32:1,
34:2, 34:1 and 34:1, were increased in mutant brain (Fig. 4B;
supplemental Table 1, available at www.jneurosci.org as supple-
mental material). A direct comparison of these PEtOH species
with the corresponding molecular species of PA (Fig. 7) revealed
a remarkable and specific increase in both PEtOH 34:2 and PA
34:2 in the brain of SwAPPmice, and since the latter increase was
rescued by PLD2 ablation, we speculate that this PA species may
be a bona fide product of a hyperactivated PLD2 in the SwAPP
brain. Interestingly, PA 34:2 is the only molecular species of PA
that was found to accumulate in Drosophila melanogaster photo-
receptors upon overexpression of PLD of the 17 species of PA
measured (Raghu et al., 2009b). Consistent with a pathogenic
role of this lipid, overexpression of the fly ortholog of PLD in the
photoreceptors results in the degeneration of photoreceptors.
Collectively, these data suggest that increased PLD levels/activity
and the resulting accumulation of PA 34:2 may be detrimental to
cell physiology, at least in some cell types. In contrast to PEtOH
34:2, other molecular species of PEtOH (i.e., 36:2, 36:1, 36:0,
38:3, 38:2 and 38:1) were not affected by SwAPP overexpres-
sion (Fig. 4B) and the corresponding PA species were equally
insensitive to the presence of the transgene (Fig. 7). Alto-
gether, this combined in vivo analysis of PEtOH and PA spe-
cies has allowed for the implication of specific PLD products
in AD. However, future studies will be required to determine
whether these lipid products are simple AD biomarkers or key
contributors to AD pathogenesis.
In addition, our LC-MS analysis uncovered interesting
changes as well as some plasticity in the metabolism of PA as a
result of PLD2 manipulation. For instance, of the two molecular
species that were significantly decreased in the Pld2/ fore-
brains (in the absence of SwAPP transgene), PA 32:1 and 38:4,
only the former is believed to be a direct product of PLD
(Hodgkin et al., 1998; Pettitt et al., 2001). Indeed, the primary
source of PA 38:4 is thought to originate fromDAG kinase in the
PLCpathway (Hodgkin et al., 1998). However, ethanol injections
led to the production of PEtOH 38:4 in mouse brain (Fig. 4B;
supplemental Table 1, available at www.jneurosci.org as supple-
mental material), suggesting that the corresponding molecular
species of PC can be a bona fide substrate for PLD in vivo. On the
other hand, hints that compensatory changes in the metabolism
of PA can occur as a result of PLD2 ablation are suggested by the
fact that knocking out PLD2 causes a modest, but significant
increase in brain PA 32:0, a phenomenon exacerbated by SwAPP
overexpression (Fig. 7; supplemental Table 2, available at www.
jneurosci.org as supplemental material). Considering the com-
plexity of PA metabolism, adaptive changes can indeed be
expected, perhaps allowing PLD2-deficient cells, tissues and or-
ganisms to cope with the deficiency of specific pools of PA that
are normally produced by PLD2. Such compensatory mecha-
nisms in the metabolism of PA may not be as efficient when
PLD is either overexpressed (Raghu et al., 2009a,b) or hyper-
activated upon stress conditions, such as during A elevation
(this study). We speculate that PLD2 ablation, which results in
a 40% decrease in brain-associated total PLD activity (supple-
mental Fig. 1C, available at www.jneurosci.org as supplemen-
tal material), may confer protection during A elevation by
correcting some of the aberrant features of PA metabolism
occurring in this condition.
Finally, our study expands on previous work showing that
blocking the action of Amay be beneficial for the treatment of
AD (Gong et al., 2006; Trinchese et al., 2008). Collectively, results
presented in this study identify PLD2 as a new player in AD
pathogenesis and, together with the lack of obvious detrimental
phenotypes in Pld2/ mice, suggest that PLD2 inhibitors may
be valuable therapeutic agents. Similarly, PLD1 inhibitorsmay be
useful for specific therapeutic avenues, as our recent mouse ge-
netic study has implicated this other isoform in the modulation
of autophagy (Dall’Armi et al., 2010), a cellular degradative path-
way involved in a growing number or human disorders, includ-
ing AD.
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